Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)

Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic therapies (e.g., for orthostatic hypotension and movement, sleep, and urinary disorders), but putative disease-modifying treatments (DMTs) (e.g., Lundbeck’s amlenetug) are emerging in the pipeline. Agents such as droxidopa, midodrine, atomoxetine, amantadine, clonazepam, and levodopa / carbidopa are prescribed as needed to alleviate the constellation of symptoms associated with the disease. This analysis will gauge their performance on key current prescribing drivers and assess the importance of and trade-offs between key clinical attributes for a future DMT.

QUESTIONS ANSWERED

• What are the most important clinical attributes influencing prescribing for MSA (e.g., impact on disease progression and motor, orthostatic, sleep, or urinary symptoms, risk of serious adverse events, delivery profile, OOP cost)?
• How do droxidopa, midodrine, atomoxetine, levodopa / carbidopa, amantadine, clonazepam, and oxybutynin perform on these attributes?
• Based on a conjoint analysis and TPP simulation, what trade-offs across key disease-modifying clinical attributes (e.g., slowing of mortality-adjusted clinical progression, reduction in brain volume loss, change in speech and quality of life scores, serious adverse event risk, and delivery profile) and price are neurologists willing to make for a hypothetical new drug to treat MSA?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in February 2026

Key drugs: Droxidopa, levodopa / carbidopa, midodrine, amantadine, clonazepam, atomoxetine, oxybutynin

Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.